Research Centers

photo

Robert E. Gerszten, MD

The Gerszten Laboratory investigates the molecular basis of injury responses in cardiovascular disease.

    Principal Investigator, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital

    Director of the Clinical and Translational Research Program, MGH Heart Center

    Associate Professor of Medicine, Harvard Medical School

    Senior Associate, Broad Institute of Harvard and MIT

    Dr. Gerszten’s research efforts focus on understanding the molecular basis of injury responses in cardiovascular disease. His laboratory has incorporated emerging proteomics and metabolomics technologies to help identify novel signals derived from leukocytes, endothelial cells, or from the myocardium. In ongoing translational studies, his group applies these same methodologies directly to samples from well-phenotyped human cohorts to identify candidate biomarkers, returning again to the bench to define functional roles. The research incorporates basic molecular and cell biology, chemistry and mass spectrometry, bioinformatics, all with a foundation in clinical medicine. The overall goal is to identify new metabolites and proteins that mark cardiovascular disease activity, shed insight into disease progression, and provide targets for therapeutic intervention.

Principal Investigator:

  • Robert E. Gerszten, MD
Postdoctoral Fellows:
  • Marita Barth, PhD
  • Greg Lewis, MD
  • Eugene Rhee, MD
Research Scientists:
  • Fjori Kristo, MD
  • Dongxiao Shen, PhD
  • Xu Shi, PhD
Technicians:
  • Alex Palma
  • Melinda Palma
Clinical Study Coordinators:
  • Maryann Martinovic
  • Laurie Farrell

  • Role of chemokines and bioactive lipids in atherosclerosis and aneurysm formation in murine and cell-based models
  • Novel protein and metabolic biomarkers of atherosclerosis
  • Novel protein and metabolic biomarkers of diabetes and its complications
  • Proteomics approaches to monocyte activation
  • Defining genetic determinants of metabolism integrating human genome wide scanning, metabolomic profiling and recombinant inbred murine strains
  • Newly discovered biomarker can predict diabetes onset

    A study led by Robert Gerszten, MD, director of clinical and translational research at the Massachusetts General Hospital Institute for Heart, Vascular and Stroke Care, identifies a biomarker that can predict diabetes risk.

    Gerszten Laboratory

    CNY 149-8
    149 13th Street
    Charlestown, MA 02129

    Phone: 617-724-8322
    Fax: 617-726-5651
    Email: rgerszten@partners.org
    Hours: Mon-Fri 8:30am-5pm

    Public Transportation Access: yes
    Disabled Access: yes

    Administrative Assistant - Colleen Squires

    Tel: 617-726-1527

    E-mail: csquires@partners.org

     

    Laboratory Manager - Sumita Sinha, PhD

    Tel: 617-726-0725

    E-mail: ssinha@partners.org

     

    patient

    Proto magazine

    Proto magazine stakes its ground on medicine's leading edge, reporting back from the frontiers of research and practice - exploring breakthroughs, dissecting controversies and opening a forum for informed debate.

    Research at Mass General

    Discover the largest hospital-based research program in the U.S. and how clinicians and scientists chart new terrain in biomedical research to treat and prevent human disease and bring the latest advances to patient care

    Work for one of the nation's top hospitals

    Discover what makes Massachusetts General Hospital not just one of the best places to receive patient care but also one of the best places to work.